Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Psilocybin-Assisted Massed CPT for Chronic PTSD
NCT06386003Phase 2Active, not recruiting
- Sponsor
- Unity Health Toronto
- Start
- Jun 2026
- Primary completion
- Jan 2028
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of psilocybin in post-traumatic stress disorder (PTSD), sponsored by Unity Health Toronto. Primary endpoint: Feasibility and tolerability at 16 weeks. Started Jun 2026; status: active, not recruiting.
02
Drugs
psilocybin
03
Conditions
post-traumatic stress disorder (PTSD)
Beyond the preview
Go deeper on NCT06386003.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06386003.